Translational Study Using Human Abdominal Adipose Tissue Biopsies to Investigate the Role of Cannabinoid Receptor 1 (CB1) in Controlling Endocannabinoid and Adipokine Secretion

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DIJON · Jun 18, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how a specific receptor in the body, called Cannabinoid Receptor 1 (CB1), affects the production of certain substances related to fat and sugar metabolism in people with type 2 diabetes and abdominal obesity. Researchers want to understand if being overweight or having diabetes leads to an overproduction of these substances, known as endocannabinoids, from fat tissue. They will also investigate whether using new medications that block CB1 can help reduce the production of these endocannabinoids.

To participate in this study, men and post-menopausal women aged 18 to 80 who are either non-diabetic obese, diabetic and obese, or healthy controls may be eligible. Participants will need to be willing to undergo a type of surgery called visceral surgery and give their consent. Throughout the study, participants can expect to have their fat tissue analyzed to learn more about the substances produced by their bodies and how these might relate to their health conditions. It's important to note that certain health conditions, like active cancer or chronic diseases, may prevent someone from joining the study.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• * Controls:
• • men or post-menopausal women aged between 18 and 80
• • gave oral consent
• • to undergo visceral surgery
• Non-diabetic obese subjects:
• • men or post-menopausal women aged between 18 and 80
• • BMI \> 30
• • gave oral consent
• • to undergo visceral surgery
• Obese diabetic subjects:
• • men or post-menopausal women aged between 18 and 80
• • type 2 diabetic not treated with Insulin or GLP-1 agonist
• • BMI \> 30
• • gave oral consent
• • to undergo visceral surgery
• Exclusion Criteria:
• * Controls:
• • Person not covered by national health insurance.
• • BMI \> 30
• • diabetes
• • chronic inflammatory disease
• • cancer undergoing chemotherapy or chemotherapy less than a year old
• • digestive cancer with recent weight loss (≥10%) and/or malnutrition
• • known metastatic cancer
• • cancer undergoing long-term hormonal treatment
• • protected adult
• Non-diabetic obese subjects:
• • Person not covered by national health insurance
• • diabetes
• • chronic inflammatory disease
• • cancer undergoing chemotherapy or chemotherapy less than a year old
• • digestive cancer with recent weight loss (≥10%) and/or malnutrition
• • known metastatic cancer
• • cancer undergoing long-term hormonal treatment
• • protected adult
• Obese diabetic subjects:
• • Person not covered by national health insurance
• • chronic inflammatory disease
• • cancer undergoing chemotherapy or chemotherapy less than a year old
• • digestive cancer with recent weight loss (≥10%) and/or malnutrition
• • known metastatic cancer
• • cancer undergoing long-term hormonal treatment
• • type 1 diabetes
• • secondary diabetes
• • protected adult